With the changing demography and growth of persons aged older than 65 years, coupled with advancing in medical therapies, we will see a stronger emphasis on evaluative research on nonpharmacologic ...

Citation Frade S, O'Neill S, Greene D, Nutter E, Cameron M. Exercise as adjunctive therapy for systemic lupus erythematosus. Cochrane Database of Systematic Reviews 2023, Issue 4. Art. No.: CD014816.

The systemic lupus erythematosus-associated NCF1 90H allele synergizes with viral infection to cause mouse lupus but also limits virus spread The induction of autoimmune symptoms may require both ...

Summary and Commentary Summary Biomarkers that reliably identify or even predict disease manifestations in systemic lupus erythematosus (SLE) are needed. In a recent issue of the Clinical Journal ...

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterised by the production of autoantibodies and the formation of immune complexes, leading to inflammation and multi-organ ...

Systemic lupus erythematosus, a.k.a. lupus, is a chronic autoimmune condition that causes the immune system to attack healthy tissues and organs. It can affect the joints, skin, kidneys, blood ...

Dr. John Watterson, MD, FRCPC, discusses diagnosis and symptoms of lupus disease. Tina Smith's Face-To-Face With 'Shocked' Mike Lee Is A Proven Way To Confront A Bully Steelers facing a major ...

People with lupus can have cognitive symptoms, like having a hard time thinking clearly or remembering things. This is also called “brain fog” or “lupus fog,” and it often comes and goes over time. In ...

Maridav/Adobe Stock Systemic lupus erythematosus, a.k.a. lupus, is a chronic autoimmune condition that causes the immune system to attack healthy tissues and organs. It can affect the joints, skin, ...

Project Summary: Childhood-onset systemic lupus erythematosus (cSLE) is a rare and severe autoimmune disease that can damage multiple organ systems. Compared to adult lupus, cSLE is more aggressive ...

Gazyva has also been filed for the lupus nephritis indication in Europe, said Roche, which is also expecting a readout from the phase 3 ALLEGORY trial in a broader SLE population later in 2025 and ...